ACY1L2 Inhibitors
Chemical inhibitors of Acylase 1-like 2 (ACY1L2) encompass a diverse range of compounds that interact with the enzyme's activity through various indirect mechanisms. Acetazolamide, by inhibiting carbonic anhydrase, alters the balance of carbonic acid and bicarbonate in cells, which can affect the pH-dependent conformation of ACY1L2. This alteration in pH can alter the enzyme's activity, impacting its ability to hydrolyze its specific substrates. Methotrexate, through its inhibition of dihydrofolate reductase, leads to a decrease in tetrahydrofolate, which is crucial for purine nucleotide biosynthesis and amino acid metabolism. This disruption can lead to an accumulation of certain amino acids or peptides, which in turn can influence the activity of ACY1L2. Triclosan inhibits fatty acid synthesis, affecting the lipid composition of membranes and potentially disrupting the optimal lipid environment necessary for ACY1L2's activity. Clomiphene, as a selective estrogen receptor modulator, can induce hormonal changes that may influence the expression levels or the availability of substrates and cofactors for ACY1L2.
Furthermore, Disulfiram, by inhibiting aldehyde dehydrogenase, increases acetaldehyde concentration, which can modify the catalytic activity of ACY1L2. The pyrimidine analog 5-Fluorouracil disrupts DNA synthesis, potentially affecting protein and peptide turnover or metabolic pathways that provide substrates for ACY1L2. Omeprazole's irreversible inhibition of H+/K+ ATPase leads to changes in gastric pH levels, which can affect the systemic pH and thus ACY1L2's activity. The tyrosine kinase inhibitor Imatinib can alter phosphorylation patterns within the cell, potentially impacting ACY1L2's stability or activity. Azathioprine, after being metabolized into mercaptopurine, inhibits purine synthesis, which can alter the balance of metabolic intermediates necessary for ACY1L2's function. Aminoguanidine's inhibition of nitric oxide synthase and formation of advanced glycation end-products can modify the cellular environment, impacting ACY1L2's structure and function. Lovastatin's inhibition of HMG-CoA reductase affects cholesterol synthesis and thus membrane fluidity, potentially altering ACY1L2's localization or interactions within the cell membrane. Lastly, Tetracycline, by inhibiting bacterial protein synthesis, can affect the production of bacterial metabolites that normally interact with ACY1L2.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acetazolamide | 59-66-5 | sc-214461 sc-214461A sc-214461B sc-214461C sc-214461D sc-214461E sc-214461F | 10 g 25 g 100 g 250 g 500 g 1 kg 2 kg | $81.00 $177.00 $434.00 $541.00 $883.00 $1479.00 $2244.00 | 1 | |
Acetazolamide inhibits carbonic anhydrase, which is involved in the reversible reaction converting carbon dioxide and water to carbonic acid. ACY1L2, being an enzyme that hydrolyzes N-acyl-homoserine lactones, a key molecule in bacterial quorum sensing, may be indirectly inhibited due to changes in pH as a result of altered carbonic acid and bicarbonate levels in the cellular environment, which can affect enzyme conformation and function. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate acts as a competitive inhibitor of dihydrofolate reductase, leading to a decrease in tetrahydrofolate and thereby affecting purine nucleotide biosynthesis and amino acid metabolism. ACY1L2, as an enzyme involved in protein and peptide metabolism, could be inhibited by the accumulation of certain amino acids or peptides that result from the disruption of folate-dependent metabolic pathways. | ||||||
Triclosan | 3380-34-5 | sc-220326 sc-220326A | 10 g 100 g | $141.00 $408.00 | ||
Triclosan is an antibacterial agent known to inhibit fatty acid synthesis by targeting enoyl-acyl carrier protein reductase. The inhibition of fatty acid synthesis can result in altered membrane compositions and indirectly disrupt membrane-associated proteins and enzymes, including ACY1L2, by altering the lipid environment necessary for their optimal activity. | ||||||
Clomiphene Citrate | 50-41-9 | sc-205636 sc-205636A | 1 g 5 g | $84.00 $176.00 | 1 | |
Clomiphene, primarily known as an ovulatory stimulant, acts as a selective estrogen receptor modulator. By competing with estrogen, it can induce a hormonal imbalance that may indirectly influence the activity of hormone-sensitive enzymes, including ACY1L2, by altering their expression or the availability of substrates and cofactors they utilize. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram inhibits aldehyde dehydrogenase, increasing acetaldehyde concentration upon alcohol intake, which could indirectly inhibit ACY1L2 by either altering its substrate specificity or by modifying its catalytic activity due to changes in cellular aldehyde levels. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. The resulting nucleotide imbalance can indirectly inhibit ACY1L2 by affecting protein and peptide turnover or by interfering with the metabolic pathways that provide the substrates for this enzyme. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole irreversibly inhibits H+/K+ ATPase in stomach parietal cells, altering gastric pH. The change in systemic pH levels can indirectly inhibit ACY1L2 by affecting the enzyme's optimal pH range for activity, potentially leading to a reduction in its hydrolytic function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. While it is primarily used to inhibit cell proliferation, it could indirectly inhibit ACY1L2 by altering phosphorylation patterns within the cell, possibly affecting the enzyme's activity or stability. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Azathioprine is metabolized into mercaptopurine, which inhibits purine synthesis. By altering the pool of purines, it could indirectly inhibit ACY1L2 by disrupting the balance of metabolic intermediates and substrates necessary for its enzymatic activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase, which could lead to reduced cholesterol synthesis. This reduction in cholesterol affects membrane fluidity and signaling pathways dependent on lipid rafts, potentially leading to an indirect inhibition of ACY1L2 by altering its localization or interactions within the cell membrane. | ||||||